Local Immunotherapies of Cancer
Fig. 28.1 The central tenants of induction of an in situ immune response to tumor antigen. First is a stimulus causing immunogenic cell death, which leads for resident or recruited…
Biology of Myeloid-Derived Suppressor Cells
Fig. 10.1 Origin of MDSCs. In the bone marrow, hematopoietic stem cells (HSC) differentiate into common myeloid progenitor (CMP) followed by granulocyte-macrophage progenitor (GMP), which give rise to immature myeloid…
Current Status of Immuno-Oncology in Hematologic Cancers
Fig. 38.1 Key time points in the discovery and development of immuno-oncology drugs for the treatment of hematologic cancers 38.2.1 The Famous CD20 Story Overcoming the barriers of xenogeneic immunogenicity…
Mutant Epitopes in Cancer
Fig. 4.1 Strategies to identify mutant epitopes from transformed cells, CSF: cerebrospinal fluid 4.2 Antigen Processing and Presentation in Cancer In order to gain an understanding of the dynamics driving…
PD1 Checkpoint Blockade in Melanoma: From Monotherapy to Combination Therapies
Fig. 19.1 Melanoma cells localized next to CD8+ T cells express PD-L1. Immunohistochemistry staining of a melanoma lymph node lesion for CD8 (brown color), labeling T cells, and PD-L1 (red…
Regulatory T Cells: Their Role, Mechanism of Action, and Impact on Cancer
Fig. 6.1 Regulatory T cells (Tregs) limit self-directed immune responses but also suppress antitumor immunity and clearance of chronic viral infections. Tregs are essential for the maintenance of peripheral tolerance…
NK Cell-Based Therapies
Fig. 16.1 NK cell-based therapies. (a). NK cells are purified from the peripheral blood of a healthy donor and activated in vitro with cytokines (IL-2 or IL-15) before being injected…
The Human Tumor Microenvironment
Fig. 2.1 Major immunopathological and genetic events occurring during carcinogenesis. Upon chronic inflammatory stimuli exposure, normal cells undergo transformation into precancerous cells. Local inflammation induces recruitment of myeloid-derived cells that…
Concluding Remarks
© Springer International Publishing AG 2018Laurence Zitvogel and Guido Kroemer (eds.)Oncoimmunologyhttps://doi.org/10.1007/978-3-319-62431-0_43 43. Concluding Remarks Pedro Romero1 and Wolf H. Fridman1 (1) Ludwig Cancer Research Center at University of Lausanne, Switzerland and Cordeliers Research Center, Paris, France …
Immunotherapy of Gliomas
Fig. 39.1 A workflow of immunotherapy discovery and combinatorial treatment approaches in neurooncology References 1. Ousman SS, Kubes P. Immune surveillance in the central nervous system. Nat Neurosci. 2012;15:1096–101.CrossrefPubMed 2….
